{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"45.9","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"45.9","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.9","upperLimit":"99.6","value":"83.3"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"64.1","value":"16.7"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Percentage of patients (who are off treatment) who experienced either a Complete Response (CR) or Partial Response (PR) during off treatment period. Per RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to \\<10 mm. Partial Response (PR): ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD):≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of ≥5 mm. The appearance ≥1 new lesion(s) is considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cabozantinib s-malate PO QD on days 1-28 of each cycle and nivolumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity. Patients also undergo a CT scan and/or MRI as well as blood sample collection throughout the trial.\n\nBiospecimen Collection: Undergo blood sample collection\n\nCabozantinib S-malate: Given PO\n\nComputed Tomography: Undergo CT\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV","id":"OG000","title":"Treatment (Cabozantinib S-malate, Nivolumab)"}],"paramType":"MEDIAN","populationDescription":"Off treatment patients who were evaluated for efficacy.","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Best Overall Response (Off Treatment)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}